Effective September 10, 2020, lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg, (Temixysā¢) has been added to the ADAP formulary. Temixysā¢ is a combination of two nucleoside analog reverse transcriptase inhibitors. Temixysā¢ is a once-daily single-tablet combination regimen used for the treatment of HIV-1 infection in combination with other antiretroviral medications. Temixysā¢ received federal Food and Drug Administration (FDA) approval in November 2018; however, it was not available in the U.S. until the last quarter of 2019. Temixysā¢ contains the same ingredients as Cimduoā¢, which is already on the ADAP formulary. The addition of Temixysā¢ will ensure that ADAP clients are not denied coverage due to the version of lamivudine/tenofovir disoproxil fumarate that is dispensed.
If you have any questions regarding the addition of this medication to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.
Thank you,
Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health